نتایج جستجو برای: il28b genotype
تعداد نتایج: 91816 فیلتر نتایج به سال:
BACKGROUND High baseline levels of IP-10 predict a slower first phase decline in HCV RNA and a poor outcome following interferon/ribavirin therapy in patients with chronic hepatitis C. Several recent studies report that single nucleotide polymorphisms (SNPs) adjacent to IL28B predict spontaneous resolution of HCV infection and outcome of treatment among HCV genotype 1 infected patients. METHO...
BACKGROUND Pegylated interferon and ribavirin for 72 weeks improve sustained virological response (SVR) in HCV genotype 1 (HCV-1) slow viral responders. Whether interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and on-treatment viral responses can identify non-rapid virological response (RVR) patients who benefit from 48 or 72 weeks of therapy remains unclear. METHODS Tre...
Twelve-week sustained viral response (SVR) rates ranging from 94% to 99% have been reported in treatmentexperienced patients infected with genotype 1 hepatitis C virus (HCV) infection following 12 to 24 weeks of therapy with sofosbuvir (Sovaldi, Gilead) and ledipasvir (fixed-dose combination) with or without ribavirin. The study population included patients with cirrhosis and those who failed p...
BACKGROUND Hepatitis C virus (HCV) is associated with a higher prevalence of steatosis compared to the general population. AIM Our aim was to assess the impact of PNPLA3 rs738409 G-allele on steatosis in HCV patients. MATERIAL AND METHODS We included 474 HCV patients treated with peginterferon plus ribavirin. PNPLA3 rs738409 was genotyped and patients were classified according to alleles an...
BACKGROUND Data on which to base definitive recommendations on the doses and duration of therapy for genotype 3 HCV/HIV-coinfected patients are scarce. We evaluated the efficacy of a lower peginterferon-α 2a dose and a shorter duration of therapy than the current standard of care in genotype 3 HCV/HIV-coinfected patients. METHODS AND FINDINGS Pilot, open-label, single arm clinical trial which...
Hepatitis C virus (HCV) can replicate in peripheral blood mononuclear cells (PBMCs), which can produce interferon to defend against virus infection. We hypothesized that dynamic gene expression in PBMCs might impact the treatment efficacy of peginterferon/ribavirin in HCV patients. PBMCs were collected at baseline, 1st week and 4th week of treatment from 27 chronic HCV-1 patients with 48-week p...
TO THE EDITOR—We read with interest the Brief Report by Dr. O'Brien and colleagues [1] of an analysis of subgroup differences in the ION-3 trial, which evaluated 8 and 12 weeks of ledipasvir-sofosbuvir in treatment-naive patients with genotype 1 hepatitis C virus (HCV). The authors note that the prescribing instructions for ledipasvir-sofosbuvir state that shortening treatment duration from 12 ...
BACKGROUND AND AIMS Genetic variations in the interleukin 28B (IL28B) gene have been associated with viral response to PEG-interferon-α/ribavirin (PR) therapy in hepatitis C virus (HCV) genotype 1 infected patients from North America, Europe and Asia. The importance of these IL28B variants for Argentine patients remains unknown. MATERIAL AND METHODS IL28B host genotypes (rs8099917 and rs12979...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید